Fresenius (FRE) Q3 2025 earnings summary

Executive summary

• Achieved strong organic revenue growth of 6% in Q3 2025, with Group revenue at €5,477 million and EBIT at €574 million, driven by robust performance in Fresenius Kabi and Fresenius Helios.

• Core EPS increased by 14% in constant currency, reflecting strong operations and lower interest expenses.

• EBIT margin improved to 10.5%, with EBIT up 6% in constant currency, accelerating from Q2 2025.

• Transformation initiatives and disciplined execution are delivering tangible results, supporting a raised full-year EBIT guidance.

• Share price surged 41% in the first nine months of 2025, outperforming major indices.

Financial highlights

• Q3 2025 revenue: €5,477 million (+6% organic), EBIT: €574 million (+6%), net income before special items: €461 million (+19%), EPS: €0.82 (+19%).

• Operating cash flow in Q3 2025: €759 million; free cash flow: €435 million; LTM operating cash flow: €2.2 billion.

• Net debt/EBITDA at 3.0x, within the target corridor.

• Q1-3 2025 revenue: €16.7 billion (+6% organic), EBIT: €1,882 million (+2%), net income: €1,443 million (+13%).

• Interest expense decreased to €81 million in Q3 2025 from €116 million in Q3 2024, supporting bottom-line growth.

Outlook and guidance

• Full-year 2025 EBIT growth guidance raised to 4–8% (previously 3–7%) at constant currency.

• Organic revenue growth expected at 5–7% for the group; Kabi targets mid- to high-single-digit growth, Helios mid-single-digit.

• Q4 2025 expected to see further EBIT acceleration, positive phasing effects, and incremental investments in R&D and CapEx.

• Cash conversion rate expected around 1.0; net debt/EBITDA to remain within 2.5x–3.0x.

• Underlying business momentum expected to continue into 2026 and beyond, driven by Biopharma, new product launches, and innovation.